Constellation Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (2008)
Status: Acquired by MorphoSys (2021)

Organization Overview

First Clinical Trial
2013
NCT01949883
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Constellation Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic-Myeloproliferative Diseases (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Primary Myelofibrosis (Phase 3)

Prostatic Neoplasms (Phase 2)

Thrombocythemia, Essential (Phase 3)

Thrombocytosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9